Use of FK506 immunosuppressive therapy in pancreas transplantation

D. S. Elmer, T. Nyman, Donna Hathaway, R. Alloway, A. O. Gaber

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The purpose of this study was to evaluate the safety, efficacy, and transplant outcomes associated with FK506 rescue and maintenance therapy in pancreas transplant recipients. A chart review was conducted on 10 patients receiving FK506 after pancreas transplantation. Transplant outcomes were compared with an equivalent group of patients receiving cyclosporine. Medication dose, side effects, infections, rejection episodes, glycemic control, and graft survival were recorded from 2 to 28 weeks after transplant. Rescue therapy was successful in the patients who were converted to FK506 prior to a significant decline in glycemic control, whereas those patients who were converted after a decline in glycemic control were required to return to exogenous insulin administration. Neurological complications, nephrotoxicity, incidence of infection, hypertension, rejection, and graft survival were similar for both groups. Use of FK506 is comparable to cyclosporine in pancreas allograft recipients and successful conversion from cyclosporine to FK506 can be undertaken for rescue therapy.

Original languageEnglish (US)
Pages (from-to)122-127
Number of pages6
JournalJournal of Transplant Coordination
Volume6
Issue number3
DOIs
StatePublished - Jan 1 1996

Fingerprint

Pancreas Transplantation
Tacrolimus
Immunosuppressive Agents
Cyclosporine
Graft Survival
Transplants
Pancreas
Therapeutics
Infection
Allografts
Insulin
Hypertension
Safety
Incidence

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Use of FK506 immunosuppressive therapy in pancreas transplantation. / Elmer, D. S.; Nyman, T.; Hathaway, Donna; Alloway, R.; Gaber, A. O.

In: Journal of Transplant Coordination, Vol. 6, No. 3, 01.01.1996, p. 122-127.

Research output: Contribution to journalArticle

Elmer, D. S. ; Nyman, T. ; Hathaway, Donna ; Alloway, R. ; Gaber, A. O. / Use of FK506 immunosuppressive therapy in pancreas transplantation. In: Journal of Transplant Coordination. 1996 ; Vol. 6, No. 3. pp. 122-127.
@article{a13d5a8fb3d34f5eb62deab0f768a10b,
title = "Use of FK506 immunosuppressive therapy in pancreas transplantation",
abstract = "The purpose of this study was to evaluate the safety, efficacy, and transplant outcomes associated with FK506 rescue and maintenance therapy in pancreas transplant recipients. A chart review was conducted on 10 patients receiving FK506 after pancreas transplantation. Transplant outcomes were compared with an equivalent group of patients receiving cyclosporine. Medication dose, side effects, infections, rejection episodes, glycemic control, and graft survival were recorded from 2 to 28 weeks after transplant. Rescue therapy was successful in the patients who were converted to FK506 prior to a significant decline in glycemic control, whereas those patients who were converted after a decline in glycemic control were required to return to exogenous insulin administration. Neurological complications, nephrotoxicity, incidence of infection, hypertension, rejection, and graft survival were similar for both groups. Use of FK506 is comparable to cyclosporine in pancreas allograft recipients and successful conversion from cyclosporine to FK506 can be undertaken for rescue therapy.",
author = "Elmer, {D. S.} and T. Nyman and Donna Hathaway and R. Alloway and Gaber, {A. O.}",
year = "1996",
month = "1",
day = "1",
doi = "10.7182/prtr.1.6.3.gw37266736430578",
language = "English (US)",
volume = "6",
pages = "122--127",
journal = "Progress in Transplantation",
issn = "1526-9248",
publisher = "InnoVision Communications",
number = "3",

}

TY - JOUR

T1 - Use of FK506 immunosuppressive therapy in pancreas transplantation

AU - Elmer, D. S.

AU - Nyman, T.

AU - Hathaway, Donna

AU - Alloway, R.

AU - Gaber, A. O.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - The purpose of this study was to evaluate the safety, efficacy, and transplant outcomes associated with FK506 rescue and maintenance therapy in pancreas transplant recipients. A chart review was conducted on 10 patients receiving FK506 after pancreas transplantation. Transplant outcomes were compared with an equivalent group of patients receiving cyclosporine. Medication dose, side effects, infections, rejection episodes, glycemic control, and graft survival were recorded from 2 to 28 weeks after transplant. Rescue therapy was successful in the patients who were converted to FK506 prior to a significant decline in glycemic control, whereas those patients who were converted after a decline in glycemic control were required to return to exogenous insulin administration. Neurological complications, nephrotoxicity, incidence of infection, hypertension, rejection, and graft survival were similar for both groups. Use of FK506 is comparable to cyclosporine in pancreas allograft recipients and successful conversion from cyclosporine to FK506 can be undertaken for rescue therapy.

AB - The purpose of this study was to evaluate the safety, efficacy, and transplant outcomes associated with FK506 rescue and maintenance therapy in pancreas transplant recipients. A chart review was conducted on 10 patients receiving FK506 after pancreas transplantation. Transplant outcomes were compared with an equivalent group of patients receiving cyclosporine. Medication dose, side effects, infections, rejection episodes, glycemic control, and graft survival were recorded from 2 to 28 weeks after transplant. Rescue therapy was successful in the patients who were converted to FK506 prior to a significant decline in glycemic control, whereas those patients who were converted after a decline in glycemic control were required to return to exogenous insulin administration. Neurological complications, nephrotoxicity, incidence of infection, hypertension, rejection, and graft survival were similar for both groups. Use of FK506 is comparable to cyclosporine in pancreas allograft recipients and successful conversion from cyclosporine to FK506 can be undertaken for rescue therapy.

UR - http://www.scopus.com/inward/record.url?scp=0029855005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029855005&partnerID=8YFLogxK

U2 - 10.7182/prtr.1.6.3.gw37266736430578

DO - 10.7182/prtr.1.6.3.gw37266736430578

M3 - Article

VL - 6

SP - 122

EP - 127

JO - Progress in Transplantation

JF - Progress in Transplantation

SN - 1526-9248

IS - 3

ER -